Pegcetacoplan associated with reduced growth rates of geographic atrophy biomarkers
Click Here to Manage Email Alerts
Key takeaways:
- Pegcetacoplan was associated with reduced growth rates of spectral-domain-OCT biomarkers for geographic atrophy for up to 24 months.
- The association was stronger with monthly vs. every other month dosing.
Intravitreal pegcetacoplan was associated with delayed atrophy of retinal pigment epithelium and photoreceptors among patients with geographic atrophy secondary to age-related macular degeneration, according to research.
“This study demonstrates the potential importance of SD-OCT imaging for assessing growth and response to treatment of GA,” Dun Jack Fu, PhD, a lecturer at University College London and investigator at Moorfields Eye Hospital, and colleagues wrote in JAMA Ophthalmology.
Researchers conducted a post hoc analysis of 11,614 spectral-domain OCT (SD-OCT) volumes from 936 participants (mean age, 78.5 years; 60.9% women) enrolled in two parallel 24-month, multicenter, randomized phase 3 studies assessing the efficacy of intravitreal pegcetacoplan in patients with geographic atrophy secondary to AMD. They used a deep-learning, automated quantitative OCT analytical platform to determine the association between pegcetacoplan and SD-OCT features of geographic atrophy.
Participants received intravitreal pegcetacoplan 15 mg per 0.1-mL or a sham injection monthly or every other month. Study outcomes included change from baseline to 24 months in area of retinal pigment epithelium and outer retinal atrophy in pegcetacoplan monthly, pegcetacoplan every other month and pooled sham groups.
According to results, pegcetacoplan was associated with reduced growth rates of SD-OCT geographic atrophy biomarkers for up to 24 months, with detectable reductions in retinal pigment epithelium and outer retinal atrophy area at every time point from 3 to 24 months vs. the sham group (pegcetacoplan monthly: –0.86 mm2; P < .001; pegcetacoplan every other month: –0.69 mm2; P < .001).
Monthly pegcetacoplan had a greater association with delayed atrophy at 24 months (pegcetacoplan monthly vs. every other month: –0.17 mm2), although researchers reported strong associations in the parafoveal and perifoveal macular regions with both monthly and every other month dosing vs. sham.
“Importantly, our data show that SD-OCT features were associated with visual outcome and that pegcetacoplan was associated with a delay in atrophy of both the RPE and the photoreceptors,” Fu and colleagues wrote. “However, an association between pegcetacoplan treatment with BCVA was not demonstrated.”
Collapse
Read more about
Click Here to Manage Email Alerts